Plant ID: NPO11144
Plant Latin Name: Centella asiatica
Taxonomy Genus: Centella
Taxonomy Family: Apiaceae
NCBI TaxonomyDB:
48106
Plant-of-the-World-Online:
1197718-2
Adaptogen; Anticonvulsant; Antidiarrhoeal; Antiinflammatory; Antipanic; Antirheumatic; Cardiac; Depurative; Diuretic; Febrifuge; Hypotensive; Nervine; Sedative; Skin; Tonic
Brazil; Madagascar; Bangladesh; Liberia; Sudan; Guinea; Mali; Cambodia; Malawi; Ethiopia; Rwanda; Tanzania; Somalia; Swaziland; Laos; Nigeria; Cameroon; Burkina Faso; Benin; Ghana; Australia; Iran; Malaysia; Thailand; Zambia; Cape Verde; Cote d'Ivoire; Togo; Zimbabwe; China; Germany; Belize; United States; Sierra Leone; Eritrea; Nepal; Uganda; Taiwan; Gambia; Philippines; Indonesia; New Caledonia; Mauritius; Sri Lanka; Mauritania; Vietnam; Gabon; Guinea-Bissau; Kenya; Namibia; New Zealand; Russia; Pakistan; Seychelles; Angola; Myanmar; Chad; Equatorial Guinea; South Africa; India; Botswana; Lesotho; Senegal; Congo; Mozambique; Colombia; Burundi; Japan; Niger; Fiji; Comoros
TSHR; NPSR1; | |
ADRA2B; GPR35; | |
RECQL; ALPL; TDP1; TERT; PKM; HSD11B1; AKR1B10; ALOX12; HSD17B1; AKR1B1; HSD17B2; HSD17B10; NOX4; HPGD; APEX1; POLB; | |
ACHE; | |
TEK; KDR; INSR; AXL; MET; SRC; FLT3; CDK1; EGFR; PIM1; NUAK1; IGF1R; AURKB; CSNK2A1; | |
CA2; CA12; CA14; CA7; CA4; | |
PPARA; | |
RORC; | |
ESR2; | |
NR1H4; | |
TYR; | |
KDM4E; | |
MMP9; MMP1; MMP2; | |
AHR; NFKB1; | |
FUT7; | |
SLC22A6; | |
LMNA; FABP5; SMAD3; THPO; FABP4; APP; HSPA1A; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.079E-09 | 4.700E-07 | CA12, CA14, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.426E-09 | 2.659E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 1.479E-08 | 4.238E-06 | CYP1A1, LMNA, MMP2, NOX4, PKM, PPARA, SMAD3, SRC, TEK, TERT |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.415E-08 | 6.336E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 4.220E-08 | 1.032E-05 | AXL, EGFR, INSR, MET, NOX4, SRC, TEK, THPO |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.085E-07 | 4.243E-05 | AXL, CDK1, CSNK2A1, EGFR, FLT3, PKM |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.407E-07 | 4.853E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4, SRC |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.620E-07 | 7.138E-05 | CA12, CA14, CA2, CA4, CA7 |
MF | GO:0005488; binding | GO:0042562; hormone binding | 4.074E-07 | 7.782E-05 | ACHE, EGFR, HSD17B1, IGF1R, INSR, PKM |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 5.074E-07 | 9.363E-05 | EGFR, IGF1R, INSR, KDR, SRC |
MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 6.275E-07 | 1.111E-04 | AHR, ESR2, NR1H4, PPARA, RORC |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.694E-07 | 1.175E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 8.161E-07 | 1.378E-04 | HPGD, MMP2, MMP9, TERT |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.854E-07 | 1.613E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.898E-06 | 2.583E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.987E-06 | 2.666E-04 | AHR, ESR2, NR1H4, PIM1, PPARA, RORC, SRC |
MF | Unclassified; | GO:0032403; protein complex binding | 1.995E-06 | 2.666E-04 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP9, PKM, PPARA, SMAD3, SRC, TSHR |
MF | Unclassified; | GO:0004872; receptor activity | 2.339E-06 | 3.032E-04 | ADRA2B, AHR, AXL, EGFR, ESR2, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, NR1H4, PPARA, RORC, TEK, TSHR |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.423E-06 | 3.104E-04 | CYP19A1, NFKB1, NR1H4, PPARA, SMAD3, TEK |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 2.979E-06 | 3.665E-04 | CA2, CA4, EGFR, HPGD, SLC22A6, TEK, TSHR |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 3.011E-06 | 3.684E-04 | EGFR, INSR, KDR |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 4.355E-06 | 5.071E-04 | APP, EGFR, KDR, NOX4, SRC, TEK, THPO |
MF | GO:0005488; binding | GO:0005524; ATP binding | 5.201E-06 | 5.899E-04 | AURKB, AXL, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, PKM, RECQL, SRC, TEK |
BP | GO:0065007; biological regulation | GO:0043393; regulation of protein binding | 5.659E-06 | 6.352E-04 | APP, AURKB, MET, MMP9, PPARA, SRC, TERT |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 6.343E-06 | 6.976E-04 | CA12, CA2, CA4, CA7 |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 9.927E-06 | 1.015E-03 | ACHE, AKR1B1, AKR1B10, CYP1A1, CYP1A2, CYP1B1, CYP2C9, EGFR, HSPA1A, PKM |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.015E-05 | 1.028E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.115E-05 | 1.105E-03 | APEX1, POLB |
BP | GO:0032502; developmental process | GO:0007568; aging | 1.233E-05 | 1.199E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB, TERT |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.470E-05 | 1.398E-03 | CA12, CA2, CA4, CA7, ESR2, MMP1, MMP2, MMP9, NR1H4, PPARA, RORC, SMAD3 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.622E-05 | 1.523E-03 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0050896; response to stimulus | GO:0071375; cellular response to peptide hormone stimulus | 1.741E-05 | 1.599E-03 | APEX1, INSR, NFKB1, PKM, SRC, TSHR |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 1.804E-05 | 1.637E-03 | APP, EGFR, INSR, KDR, NOX4, SMAD3, SRC |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.911E-05 | 1.705E-03 | ACHE, APP, CSNK2A1, EGFR, ESR2, FLT3, HPGD, IGF1R, KDR, MET, MMP9, NFKB1, PKM, SLC22A6, SMAD3, TERT, TYR |
BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 2.913E-05 | 2.468E-03 | ADRA2B, CDK1, EGFR, FLT3, INSR, NOX4, SRC |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 3.057E-05 | 2.578E-03 | ACHE, CDK1, CYP1A1, EGFR, PPARA, SMAD3 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.338E-05 | 2.743E-03 | CA2, CA7 |
BP | GO:0000003; reproduction | GO:0022414; reproductive process | 3.487E-05 | 2.844E-03 | ADRA2B, AKR1B1, ALPL, APP, AXL, CDK1, CYP19A1, CYP1A1, EGFR, HPGD, HSD17B2, INSR, MMP2, MMP9, SRC |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 3.501E-05 | 2.844E-03 | CDK1, EGFR, IGF1R, INSR |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 3.980E-05 | 3.163E-03 | AHR, PPARA, TERT |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 4.083E-05 | 3.222E-03 | ALPL, EGFR, MMP2, MMP9, TEK |
MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 4.625E-05 | 3.566E-03 | ESR2, NR1H4, PPARA, RORC |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 5.631E-05 | 4.297E-03 | ACHE, AKR1B1, APEX1, APP, CA4, EGFR, HSPA1A, NOX4, SRC, TYR |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 5.643E-05 | 4.297E-03 | APP, EGFR, INSR, KDR, SLC22A6, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 6.138E-05 | 4.593E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0032501; multicellular organismal process | GO:0010634; positive regulation of epithelial cell migration | 6.341E-05 | 4.712E-03 | KDR, MET, MMP9, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 6.661E-05 | 4.847E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.661E-05 | 4.847E-03 | CYP1A2, CYP2C9 |
MF | GO:0005488; binding | GO:0051425; PTB domain binding | 6.661E-05 | 4.847E-03 | APP, INSR |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 7.640E-05 | 5.419E-03 | ESR2, NR1H4, PPARA, RORC, SRC |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 7.640E-05 | 5.419E-03 | EGFR, IGF1R, INSR, KDR, TEK |
BP | GO:0023052; signaling | GO:0023057; negative regulation of signaling | 8.043E-05 | 5.631E-03 | ACHE, ADRA2B, EGFR, ESR2, GPR35, HSPA1A, IGF1R, LMNA, MET, MMP9, NR1H4, SMAD3, SRC, TERT |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.019E-04 | 6.977E-03 | AHR, APP, EGFR, IGF1R, INSR, SMAD3, TSHR |
BP | GO:0032502; developmental process | GO:0009888; tissue development | 1.108E-04 | 7.445E-03 | ALPL, CYP1B1, FABP5, INSR, KDR, PKM, PPARA, RORC, SMAD3 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 1.248E-04 | 8.242E-03 | AXL, IGF1R, INSR |
BP | GO:0009987; cellular process | GO:0051262; protein tetramerization | 1.364E-04 | 8.891E-03 | ACHE, HSD17B10, IGF1R, INSR, PKM |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 1.384E-04 | 8.941E-03 | FLT3, SRC, TEK |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.528E-04 | 9.759E-03 | CYP1A2, EGFR, MMP9 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.457E-10 | 3.858E-08 | HSD17B1, INSR, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 7.248E-10 | 5.689E-08 | HSD11B1, HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 4.165E-09 | 1.635E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.122E-07 | 6.664E-06 | MMP1, SRC, MMP2, MMP9, EGFR |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.861E-09 | 9.739E-08 | CA12, CA2, CA4, CA7, CA14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 8.234E-07 | 2.155E-05 | SRC, MMP2, MMP9, EGFR, ESR2, HSPA1A |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.233E-06 | 8.569E-05 | SMAD3, FLT3, MMP1, MMP2, MET, MMP9, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 4.233E-06 | 8.307E-05 | SRC, MMP2, KDR, MMP9, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 5.458E-06 | 8.569E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 7.687E-06 | 1.006E-04 | AKR1B1, ALOX12, TYR, CYP19A1, HSD17B10, HSD11B1, CYP2C9, FUT7, PKM, AKR1B10, HSD17B1, HSD17B2, CYP1A2, CYP1A1, ALPL |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.927E-06 | 8.307E-05 | HSD11B1, CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 8.804E-06 | 1.063E-04 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 2.067E-05 | 2.222E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.975E-06 | 9.955E-05 | HSD11B1, CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 2.123E-05 | 2.222E-04 | INSR, TEK, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.600E-05 | 2.551E-04 | HPGD, FLT3, MMP9, MET, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.174E-04 | 9.214E-04 | INSR, KDR, TEK, MET, EGFR, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 6.677E-05 | 6.167E-04 | PKM, FLT3, MET, EGFR |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 7.078E-05 | 6.173E-04 | SRC, MET, EGFR, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.275E-04 | 2.337E-03 | SMAD3, MMP2, PIM1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.037E-04 | 2.756E-03 | PIM1, CYP1B1, MMP9, MET, EGFR, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 7.495E-05 | 6.193E-04 | FABP4, FABP5, MMP1, PPARA |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 5.404E-04 | 3.394E-03 | POLB, PKM, SRC, CDK1, NFKB1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 5.054E-04 | 3.306E-03 | SRC, KDR, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 9.245E-04 | 5.184E-03 | SMAD3, INSR, EGFR, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.306E-03 | 6.215E-03 | SMAD3, SRC, MMP9, NFKB1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.971E-04 | 2.221E-03 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 8.031E-04 | 4.850E-03 | FABP4, INSR, TSHR |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 8.458E-04 | 4.918E-03 | FLT3, PIM1, NFKB1 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 1.699E-03 | 7.411E-03 | THPO, FLT3, KDR, MET, EGFR |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.185E-03 | 6.215E-03 | INSR, HSPA1A, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.295E-03 | 6.215E-03 | SMAD3, EGFR, NFKB1 |
09160 Human Diseases | 09162 Immune diseases | hsa05321 | Inflammatory bowel disease (IBD) | 1.239E-03 | 6.215E-03 | SMAD3, RORC, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.599E-03 | 7.386E-03 | MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.665E-03 | 7.411E-03 | SRC, NFKB1, ESR2 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.239E-03 | 6.215E-03 | CYP2C9, CYP1A2, CYP1A1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; TERT; KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; KDR; EGFR; MMP2; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; NFKB1; INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
C00-D49: Neoplasms | Prostate cancer | C61 | TERT; FLT3; EGFR; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; TERT; FLT3; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; TEK; MMP9; EGFR; SRC; PKM; MMP2; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; TERT; AHR; SRC; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; TEK; MMP9; EGFR; SRC; MMP2; APP; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; MMP1; TYR; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; EGFR; SRC; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; TERT; KDR; FLT3; INSR; EGFR; CYP19A1; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; EGFR; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; ALPL; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP; |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
NA: NA | GIST | NA | FLT3; |
NA: NA | Geographic retinal atrophy | NA | APP; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; MMP1; |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; APP; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TERT; KDR; EGFR; AKR1B1; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; INSR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; INSR; AKR1B1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; INSR; PKM; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
NA: NA | HIV infections | NA | AHR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; APP; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; MMP2; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; HSD11B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
C00-D49: Neoplasms | Melanoma | C43 | TERT; KDR; EGFR; TYR; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1; INSR; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; APP; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT; KDR; FLT3; EGFR; MMP2; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
NA: NA | Edema | NA | CA2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |